Quick Answer
Xenon Pharmaceuticals Inc. reported Net Income Loss of -$345.91 million for the year ending 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -47.6% in Net Income Loss from 2024 to 2025.
- This data is from Xenon Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$9.16 million | Q2 2015: $1.17 million | Q3 2015: -$3.83 million | Q4 2015: -$3.94 million | Q1 2016: -$3.26 million | Q2 2016: -$6.02 million | Q3 2016: -$7.71 million | Q4 2016: -$6.00 million | Q1 2017: -$7.52 million | Q2 2017: -$7.38 million | Q3 2017: -$7.74 million | Q4 2017: -$8.07 million | Q1 2018: -$3.76 million | Q2 2018: -$7.80 million | Q3 2018: -$14.38 million | Q1 2019: -$11.34 million | Q2 2019: -$10.01 million | Q3 2019: -$8.87 million | Q1 2020: -$7.48 million | Q2 2020: -$175.0 thousand | Q3 2020: -$8.86 million | Q1 2021: -$15.76 million | Q2 2021: -$22.11 million | Q3 2021: -$15.45 million | Q1 2022: -$19.67 million | Q2 2022: -$31.16 million | Q3 2022: -$37.15 million | Q1 2023: -$41.73 million | Q2 2023: -$47.46 million | Q3 2023: -$48.46 million | Q1 2024: -$47.93 million | Q2 2024: -$57.92 million | Q3 2024: -$62.79 million | Q1 2025: -$65.05 million | Q2 2025: -$84.71 million | Q3 2025: -$90.90 million.
- Over the full 14 years of available data (2012 to 2025), Xenon Pharmaceuticals Inc.'s Net Income Loss has declined by 7,942.5%.
- Historical annual values: Fiscal year 2025: -$345.91 million | Fiscal year 2024: -$234.33 million | Fiscal year 2023: -$182.39 million | Fiscal year 2022: -$125.37 million | Fiscal year 2021: -$78.88 million | Fiscal year 2020: -$28.84 million | Fiscal year 2019: -$41.60 million | Fiscal year 2018: -$34.50 million | Fiscal year 2017: -$30.70 million | Fiscal year 2016: -$23.00 million | Fiscal year 2015: -$15.75 million | Fiscal year 2014: $13.02 million | Fiscal year 2013: $12.03 million | Fiscal year 2012: -$4.30 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: